Published in Bone on March 15, 2010
NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases. Adv Protein Chem Struct Biol (2016) 0.78
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. Invest New Drugs (2015) 0.77
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. Invest New Drugs (2011) 0.75
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol (2004) 2.48
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates. Kidney Int (2005) 2.25
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Bisphosphonates: preclinical review. Oncologist (2004) 2.08
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res (1994) 1.84
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer (2000) 1.78
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res (2006) 1.71
Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun (2005) 1.69
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res (2004) 1.52
Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res (2005) 1.38
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia (1996) 1.33
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev (2006) 1.29
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast (2007) 1.18
Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev (2000) 1.17
In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem (2003) 1.16
Preclinical models of bone metastases. Semin Oncol (2001) 1.13
Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res (2003) 1.11
Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des (2002) 1.01
Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res (2001) 0.98
A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol (1997) 0.98
Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer (2006) 0.93
Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet (2003) 0.91
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone (2008) 0.90
Zoledronic acid: a review of its use in breast cancer. Drugs (2008) 0.88
Bone as an effect compartment : models for uptake and release of drugs. Clin Pharmacokinet (2003) 0.86
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat (2002) 0.85
A primer of bone metastases management in breast cancer patients. Curr Oncol (2008) 0.84
The antitumor potential of bisphosphonates. Semin Oncol (2002) 0.83
Emerging strategies in bone health management for the adjuvant patient. Semin Oncol (2007) 0.82
Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med (1996) 0.82
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res (2006) 0.80
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res (2001) 0.80
Local effects of malignancy on bone. Curr Opin Endocrinol Diabetes Obes (2007) 0.78
Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J Cancer Res Clin Oncol (1986) 0.77
Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma (1998) 0.76
Unmet needs in metastatic bone disease and its complications: is progress possible? Semin Oncol (2001) 0.76
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst (2002) 3.39
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol (2006) 2.95
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst (2008) 2.94
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation (2002) 2.93
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res (2007) 2.66
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Centrosome amplification and the development of cancer. Oncogene (2002) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol (2007) 2.43
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat Cell Biol (2009) 2.38
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest (2004) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res (2006) 2.27
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates. Kidney Int (2005) 2.25
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol (2005) 2.20
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem (2008) 2.12
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12